Rs to adverse drug reactions reporting in community pharmacy settings in Dhaka, BangladeshMohammad Nurul Amin,1

Rs to adverse drug reactions reporting in community pharmacy settings in Dhaka, BangladeshMohammad Nurul Amin,1 Tahir Mehmood Khan,2 Syed Masudur Rahman Dewan,1 Mohammad Safiqul Islam,1 Mizanur Rahman Moghal,1 Extended Chiau Ming3,To cite: Amin MN, Khan TM, Dewan SMR, PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21330118 et al. Crosssectional study exploring barriers to adverse drug reactions reporting in community pharmacy settings in Dhaka, Bangladesh. BMJ Open 2016;6:e010912. doi:10.1136bmjopen-2015010912 Prepublication history for this paper is obtainable on the net. To view these files please stop by the journal on the internet (http:dx.doi.org10.1136 bmjopen-2015-010912). Received 21 December 2015 Revised 29 March 2016 Accepted 29 AprilABSTRACT Objectives: To assess community pharmacists’pharmacy technicians’ understanding and perceptions about adverse drug reactions (ADRs) and barriers towards the reporting of such reactions in Dhaka, Bangladesh. System: A cross-sectional study was planned to strategy potential respondents for the study. A selfadministered questionnaire was delivered to community pharmacistspharmacy technicians (N=292) practising in Dhaka, Bangladesh. Benefits: The overall response towards the survey was 69.five (n=203). The majority in the sample was comprised of pharmacy technicians (152, 74.9 ) who possessed a diploma in pharmacy, followed by pharmacists (37, 18.two ) and others (12, 5.9 ). Overall, 72 (35.5 ) with the respondents disclosed that they had seasoned an ADR at their pharmacy, but greater than half (105, 51.7 ) weren’t acquainted with the existence of an ADR reporting body in Bangladesh. Exploring the barriers to the reporting of ADRs, it was revealed that the leading four barriers to ADR reporting had been `I usually do not understand how to report (Relative Significance Index (RII)=0.998)’, `reporting forms are not obtainable (0.996)’, `I am not motivated to report (0.997)’ and `Unavailability of professional environment to talk about about ADR (RII=0.939)’. Additionally to these, a majority (141, 69.46 ) weren’t confident about the classification of ADRs (RII=0.889) and have been afraid of legal liabilities connected with reporting ADRs (RII=0.806). Moreover, a lack of information about pharmacotherapy along with the detection of ADRs was an additional key factor hindering their reporting (RII=0.731). Conclusions: The Directorate of Drug Administration in Bangladesh must take into consideration the results of this study to assist it HMN-176 improve and simplify ADR reporting in Bangladeshi community pharmacy settings.Strengths and limitations of this studyFindings from the current study will help policymakers to understand the challenges to adverse drug reactions (ADRs) reporting in community pharmacy settings and hence to intervene to create the ADR reporting approach easier and more accessible to pharmacists and pharmacy technicians practising in Bangladesh. The Directorate of Drug Administration in Bangladesh can make the ADR reporting method far more efficient by making the reporting types less complicated to access. Moreover, offered that unavailability of an expert atmosphere to go over about ADR was a major barrier identified to the reporting of ADRs, the Bangladeshi Pharmacy Association and registration councils can play a proactive role in organising frequent continuous education and training events where pharmacists get the chance to discuss such experiences with other pharmacists. Among the possible limitations is the small quantity of pharmacists who participated in this study. Nonetheless, the entire sample was representative of Banglades.